Navigation Links
Genome changes tracked during multiple myeloma initiation, progression and treatment

Scientists have made significant progress toward elucidating key genetic events associated with the development and progression of multiple myeloma (MM), an incurable malignancy that is the second most common cancer of the blood. The results, published in the April issue of Cancer Cell, provide new genetic and biological insights that open innovative directions for the discovery of effective therapeutics that can be targeted to specific MM patients based on genetic perturbations known to contribute to MM pathogenesis.

Although genetic screening studies have provided some insight into the pathogenesis that underlies MM, the full landscape of genomic events driving cancer initiation, progression, and response to treatment have remained hidden from view. Drs. Ron A. DePinho from the Dana-Farber Cancer Institute, Cameron Brennan of Memorial Sloan-Kettering Cancer Center, and John Shaughnessy of the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences and their colleagues performed a high-resolution and integrated analysis of gene copy number alterations and expression profiles of outcome-annotated MM clinical specimens.

The researchers discovered a high level of molecular heterogeneity typified by many new recurrent amplifications and deletions that point to a large number of yet-to-be-discovered oncogenes and tumor suppressor genes. These amplification and deletion patterns define new disease subgroups of MM that are characterized by varied dysregulation of distinct cancer-relevant genes and can be correlated with different clinical outcomes. Importantly, several candidate genes identified in this study possess broad clinical and biological relevance, as they are also associated with histologically unrelated malignancies such as pancreatic, lung, breast, and ovarian cancer and may thus represent a rite of passage for many different cancers.

"This integrated and detailed view of the MM genome is consisten t with the concept of widespread changes in the expression of genes with cancer activity in the pathogenesis of MM, a concept with therapeutic and diagnostic implication for MM in particular and cancer in general," explains Dr. DePinho. The researchers suggest that on a broader scale in relation to the human cancer genome project, their results will serve to direct costly sequencing efforts toward those specific regions that contain genes displaying high pathogenic relevance. "This story clearly indicates that we are dealing with the tip of the iceberg when it comes to the universe of cancer genes," says Dr. DePinho.


'"/>

Source:Cell Press


Related biology news :

1. Genome of deadly amoeba shows surprising complexity, evidence of lateral gene transfer
2. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
3. Genome-wide mouse study yields link to human leukemia
4. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
5. Multiple Campylobacter Genomes Sequenced
6. Analysis Of Human Genome To Predict The Development Of Illnesses
7. Whole genome promoter mapping - Human Genome Project v2.0?
8. Genome study of beneficial microbe may help boost plant health
9. Candida albicans Genome Fully Annotated
10. Genome Sequence for Haemophilus Influenzae Completed
11. NHGRI Selects 13 More Organisms for Genome Sequencing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2019)... ... January 03, 2019 , ... Over the last ... their drug discovery research workflows with biology ranging from single cell-type spheroids to ... in vitro studies, they create several challenges that need to be overcome in ...
(Date:12/25/2018)... , ... December 24, 2018 , ... ... The Rockefeller University have discovered a new use for a long-standing computational concept ... spam control, blocking unwanted files and messages. Using blacklisting as a filter to ...
(Date:12/19/2018)... ... , ... InTouchMD’s flagship product, Pulse , has been honored by PM360 ... is featuring the recognition in its 7th annual Innovations issue, created for purpose of ... medical device industries. , “This recognition comes at an exciting time for Pulse as ...
Breaking Biology News(10 mins):
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. ... Disease drug candidate, code-named "KM-819." KM-819 is an orally active small molecule ... in South Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study ...
(Date:12/20/2018)... ... , ... New Year’s brings reflection and desire to improve for individuals and ... (EU) on the horizon, Jim Kasic, president and CEO of Boulder iQ, suggests five ... Device Regulation (MDR), digital health, and big data are just a few of the ...
(Date:12/18/2018)... ... ... Patients with early stages of breast cancer who undergo partial breast proton ... irradiation, a new study suggests. , Patients with early stage breast cancer — stage ... the cancerous tumor because there is a 30 to 40 percent change the disease ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial ... (human) ingredient. This has been part of their strategic plan and an important ... certification creates custom fermentation opportunities for MDG within the $44 Billion human probiotic ...
Breaking Biology Technology: